ID: ALA3218913

Max Phase: Preclinical

Molecular Formula: C31H38N6O3

Molecular Weight: 542.68

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCCOc1cccc(-n2cc3nc(-c4cccnc4C)n(C[C@H]4CCCN(C[C@H]5CCCO5)C4)c(=O)c3n2)c1

Standard InChI:  InChI=1S/C31H38N6O3/c1-3-15-39-25-10-4-9-24(17-25)37-21-28-29(34-37)31(38)36(30(33-28)27-12-5-13-32-22(27)2)19-23-8-6-14-35(18-23)20-26-11-7-16-40-26/h4-5,9-10,12-13,17,21,23,26H,3,6-8,11,14-16,18-20H2,1-2H3/t23-,26+/m0/s1

Standard InChI Key:  UPZXWEJIJAQUBN-JYFHCDHNSA-N

Associated Targets(Human)

Ghrelin receptor 6229 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HERG 29587 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Liver microsome 8277 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 542.68Molecular Weight (Monoisotopic): 542.3005AlogP: 4.63#Rotatable Bonds: 9
Polar Surface Area: 87.30Molecular Species: BASEHBA: 9HBD: 0
#RO5 Violations: 1HBA (Lipinski): 9HBD (Lipinski): 0#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 8.63CX LogP: 3.91CX LogD: 2.65
Aromatic Rings: 4Heavy Atoms: 40QED Weighted: 0.30Np Likeness Score: -1.38

References

1. McCoull W, Barton P, Broo A, Brown AJH, Clarke DS, Coope G, Davies RDM, Dossetter AG, Kelly EE, Knerr L, MacFaul P, Holmes JL, Martin N, Moore JE, Morgan D, Newton C, Osterlund K, Robb GR, Rosevere E, Selmi N, Stokes S, Svensson TS, Ullah VBK, Williams EJ.  (2013)  Identification of pyrazolo-pyrimidinones as GHS-R1a antagonists and inverse agonists for the treatment of obesity,  (2): [10.1039/C2MD20340E]

Source